Patents Assigned to Lithera, Inc.
-
Patent number: 8420625Abstract: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.Type: GrantFiled: April 28, 2011Date of Patent: April 16, 2013Assignee: Lithera, IncInventor: John Daniel Dobak
-
Patent number: 8404750Abstract: Provided herein are pharmaceutical formulations, methods, and systems for treating regional fat deposits and fat-related conditions and indications. Methods comprise administering a pharmaceutical formulation consisting essentially of a long-acting beta-2 adrenergic receptor agonist, for example, salmeterol, suitable for subcutaneous administration. Methods further comprise administering a pharmaceutical formulation that is suitable for subcutaneous injection comprising: (a) a lipophilic long-acting selective beta-2 adrenergic receptor agonist and/or glucocorticosteroid, or a salt, optical isomer, racemate, solvate, or polymorph thereof; and (b) at least one subcutaneously acceptable inactive ingredient.Type: GrantFiled: October 28, 2011Date of Patent: March 26, 2013Assignee: Lithera, Inc.Inventors: John Daniel Dobak, Kenneth Walter Locke
-
Publication number: 20120178819Abstract: Provided herein are pharmaceutical and cosmetic formulations and methods for regional adiposity reduction and treatment of body contour defects such as abdominal bulging; comprising an injectable formulation, said formulation comprising: an active ingredient that consists essentially of an adipose tissue-reducing amount of one or more lipophilic long-acting selective beta-2 adrenergic receptor agonists, or salts, solvates, or polymorphs thereof; and one or more subcutaneously acceptable inactive ingredients.Type: ApplicationFiled: November 22, 2011Publication date: July 12, 2012Applicant: Lithera, Inc.Inventors: John Daniel Dobak, Kenneth Walter Locke
-
Publication number: 20120046256Abstract: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.Type: ApplicationFiled: August 5, 2011Publication date: February 23, 2012Applicant: Lithera, Inc.Inventor: John Daniel Dobak
-
Publication number: 20120046257Abstract: Provided herein are pharmaceutical formulations, methods, and systems for treating regional fat deposits and fat-related conditions and indications. Methods comprise administering a pharmaceutical formulation consisting essentially of a long-acting beta-2 adrenergic receptor agonist, for example, salmeterol, suitable for subcutaneous administration. Methods further comprise administering a pharmaceutical formulation that is suitable for subcutaneous injection comprising: (a) a lipophilic long-acting selective beta-2 adrenergic receptor agonist and/or glucocorticosteroid, or a salt, optical isomer, racemate, solvate, or polymorph thereof; and (b) at least one subcutaneously acceptable inactive ingredient.Type: ApplicationFiled: October 28, 2011Publication date: February 23, 2012Applicant: Lithera, Inc.Inventors: John Daniel Dobak, Kenneth Walter Locke
-
Publication number: 20120015918Abstract: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.Type: ApplicationFiled: April 28, 2011Publication date: January 19, 2012Applicant: Lithera, Inc.Inventor: John Daniel Dobak
-
Publication number: 20110224176Abstract: Provided herein are lyophilized cake forms of fluticasone, salmeterol, or a pharmaceutically acceptable salt or a combination thereof which provides room temperature stability for an extended period of time. Upon reconstitution with an acceptable solvent (e.g., a carrier or diluent), the reconstituted pharmaceutical or cosmetic formulation provides a sterile, non-suspension form suitable for parenteral injectable administration, including subcutaneous injection.Type: ApplicationFiled: January 14, 2011Publication date: September 15, 2011Applicant: Lithera, Inc.Inventors: John Daniel Dobak, Chris Kemmerer, Kenneth Walter Locke
-
Publication number: 20110130373Abstract: Provided herein are pharmaceutical formulations, methods, and systems for treating regional fat deposits and fat-related conditions and indications. Methods comprise administering a pharmaceutical formulation consisting essentially of a long-acting beta-2 adrenergic receptor agonist, for example, salmeterol, suitable for subcutaneous administration. Methods further comprise administering a pharmaceutical formulation that is suitable for subcutaneous injection comprising: (a) a lipophilic long-acting selective beta-2 adrenergic receptor agonist and/or glucocorticosteroid, or a salt, optical isomer, racemate, solvate, or polymorph thereof; and (b) at least one subcutaneously acceptable inactive ingredient.Type: ApplicationFiled: May 26, 2010Publication date: June 2, 2011Applicant: LITHERA, INC.Inventors: John Daniel Dobak, Kenneth Walter Locke
-
Publication number: 20110105446Abstract: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.Type: ApplicationFiled: April 19, 2010Publication date: May 5, 2011Applicant: LITHERA, INC.Inventor: John Daniel Dobak
-
Patent number: 7829554Abstract: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.Type: GrantFiled: July 13, 2006Date of Patent: November 9, 2010Assignee: Lithera, Inc.Inventor: John D. Dobak